Why Farbe Firma is the Top Manufacturer of Nicardipine HCL Injection
- Maulik Sudani
- 7 hours ago
- 8 min read
Last Updated: June 19, 2026
TL;DR: Nicardipine HCL Injection — a sterile, clear, pale-yellow aqueous solution of nicardipine hydrochloride, a dihydropyridine calcium channel blocker and arterial vasodilator, supplied commonly as a 2.5 mg/mL solution in a 25 mg/10 mL ampoule or vial and diluted before a slow, titrated continuous intravenous infusion — is a frontline hospital agent for the short-term control of acute and severe hypertension, hypertensive emergencies and perioperative blood-pressure control when oral therapy is not feasible. Because the patient is often acutely unstable, the drug is given as a closely titrated infusion under continuous blood-pressure monitoring and nicardipine is a light-sensitive dihydropyridine, each ampoule must deliver an exact, sterile, particulate-free dose at the labelled concentration, with the assay, the photodegradation and related-substance profile, solution pH, fill volume, low particulate and endotoxin, a validated sterilisation route, light-protective packaging and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Nicardipine HCL Injection at our Gujarat, India facility and supplies it to emergency, cardiology, neurocritical-care, anaesthesia and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Dihydropyridine calcium channel blocker / arterial vasodilator (nicardipine hydrochloride) — Nicardipine HCL Injection is diluted and given as a slow, titrated continuous intravenous infusion under continuous blood-pressure monitoring for the short-term management of acute and severe hypertension, hypertensive emergencies and perioperative blood-pressure control, where smooth, precise, reproducible dosing is essential.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated light-protected compounding and ampoule/vial filling lines, control of the stability-indicating assay, the photodegradation and related-substance profile, solution pH, fill volume, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution ampoule and vial contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Nicardipine HCL Injection Demands a Premium Manufacturer
Nicardipine HCL Injection holds a critical, time-sensitive place in emergency departments, cardiology services, neurocritical-care units and operating theatres across every market. It is the intravenous calcium channel blocker that clinicians reach for when blood pressure must be brought down quickly but smoothly — in a hypertensive emergency, in acute severe hypertension, or to hold blood pressure within a tight target during and after surgery — situations where an abrupt, overshooting fall in pressure is as dangerous as the high pressure itself. As a dihydropyridine arterial vasodilator given as a titratable continuous infusion, nicardipine lets a treating team dial blood pressure to target in real time and hold it there. In each of these settings the dose delivered from each ampoule must be exact, sterile, particulate-free and reliably the same from unit to unit, because safe titration in an unstable patient depends on a precise, reproducible concentration given without delay.
That clinical reality places real demands on the manufacturer. Nicardipine HCL Injection is a low-strength, clear aqueous solution — commonly 2.5 mg/mL in a 25 mg/10 mL presentation — that is diluted before continuous infusion, so the assay must be exact at low concentration, the impurity and degradation profile must stay within tight limits, and the solution pH must be held in the controlled, slightly acidic range that keeps nicardipine soluble and stable. Critically, nicardipine is a dihydropyridine, a chemical class that is intrinsically light-sensitive, so the manufacturer must protect the product from light throughout compounding, filling and storage, run a validated ICH Q1B photostability programme, and package the ampoule or vial to shield it from light on the shelf and at the bedside. The solution must be free of visible and sub-visible particulates and low in endotoxin, the fill volume accurate so each unit delivers the labelled content, and the right sterilisation route — terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing — selected and validated. Choosing a Nicardipine HCL Injection manufacturer that treats the stability-indicating assay, photostability and light-protective packaging, pH control, fill-volume accuracy, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Nicardipine HCL Injection Manufacturer Apart
A world-class manufacturer of Nicardipine HCL Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of nicardipine hydrochloride with related-substance and photodegradation control by validated HPLC — accurate even at the low 2.5 mg/mL strength — that a light-sensitive acute cardiovascular medicine demands, a robust, validated, light-protected sterilisation and fill process that protects sterility, pH and clarity in a photolabile aqueous solution, and tender-ready dossier support for a high-volume hospital-formulary cardiovascular product procured through pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial-grade nicardipine hydrochloride sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend the assay, the pH and the photostability of a low-strength solution. The bulk solution is compounded in water-for-injection at the controlled, slightly acidic pH that keeps nicardipine hydrochloride soluble and stable, sterile-filtered through 0.22 µm membrane, and filled into ampoules or vials under ISO Class 5 conditions with the workflow shielded from light, with the validated sterilisation route — terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing — locked in the master batch record. Filled units are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of nicardipine hydrochloride by validated HPLC, the related-substance and photodegradation profile, solution pH, deliverable (fill) volume, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for intravenous infusion. Because nicardipine is light-sensitive and the strength is low, assay accuracy, photostability, light-protective packaging and container-closure integrity are validated together so the assay, colour and clarity stay within specification across shelf life.
Quality Systems Behind Every Nicardipine HCL Injection
Every Farbe Firma Nicardipine HCL Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of nicardipine hydrochloride against pharmacopoeial reference standards, control of related substances and photodegradation products by HPLC, solution pH, clarity and colour of the solution, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule or vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated light-protected filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because nicardipine hydrochloride injection is a low-strength, light-sensitive intravenous cardiovascular medicine and the assay, photodegradation profile, pH, particulate and endotoxin burden drive both efficacy and safety, we treat the stability-indicating assay, the photodegradation profile, the solution pH and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with a full ICH Q1B photostability challenge, so the assay, colour, clarity and pH stay within specification across the labelled shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Nicardipine HCL Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad emergency, cardiology and critical-care small-volume parenteral portfolio. For Nicardipine HCL Injection specifically, we supply the 2.5 mg/mL solution in the 25 mg/10 mL ampoule and vial presentation under WHO-GMP conditions, with country-specific strengths, fill configurations, light-protective tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, photodegradation, pH, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, translated package inserts and artwork — including dilution-before-infusion and protect-from-light handling warnings — for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Nicardipine HCL Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development at low strength, related-substance and photodegradation control, pH and solubility formulation design, light-protective process and packaging engineering, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For an acute cardiovascular medicine where assay accuracy, photostability, pH control and particulate control directly govern both efficacy and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Nicardipine HCL Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Nicardipine HCL Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated light-protected compounding and ampoule/vial filling lines, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Nicardipine HCL Injection do you supply?
Our standard presentation is the 2.5 mg/mL solution of nicardipine hydrochloride in a 25 mg/10 mL ampoule or vial, diluted before slow continuous intravenous infusion. Custom strengths, fill configurations, ampoule and vial formats, light-protective tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Nicardipine HCL Injection mainly used for?
Nicardipine HCL Injection is used for the short-term control of acute and severe hypertension, hypertensive emergencies and perioperative blood-pressure control when oral therapy is not feasible. It is a dihydropyridine calcium channel blocker given as a slow, titrated continuous intravenous infusion under blood-pressure monitoring; Farbe Firma verifies the assay, photodegradation profile, pH, deliverable volume, particulate matter and endotoxin at release so each ampoule delivers a precise, reproducible dose.
Can Farbe Firma support country-specific registrations for Nicardipine HCL Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Nicardipine HCL Injection contract manufacturing?
MOQs vary by strength, ampoule or vial size, sterilisation route, light-protective packaging, label complexity and dossier requirements. For our acute cardiovascular small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments